Skip to main content
SpringerLink
Log in

Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion

  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Primary hepatocellular carcinoma is one of the most common malignancies worldwide. Isolated hepatic perfusion (IHP) is a regional treatment technique that isolates the organ to allow delivery of high-dose chemotherapy, biological agents, and hyperthermia directly to unresectable cancers confined to the liver. This study presents our experience using IHP with melphalan with or without tumor necrosis factor (TNF) to treat patients with hepatocellular carcinoma or adenocarcinoma of hepatobiliary origin. Nine patients with unresectable primary hepatic malignancies underwent a 60-minute IHP with 1.5 mg/kgmelphalan with or without 1.0 mg TNF. Four patients failed one or more previous treatment regimens, and the mean hepatic replacement by tumor was 41% (range 10% to 75%). Patients were monitored for response, toxicity, time to recurrence, and survival. Six (67%) of nine patients experienced greater than 50% regression of tumor by objective radiographic imaging and an additional patient had a 45% reduction in tumor burden. Mean time to progression was 7.7 months for those who responded to treatment. Patients who had a response to therapy had an average overall survival of 16.3 months. IHP can be performed safely and has significant antitumor activity in patients with unresectable primary hepatic malignancies. Hepatic progession continues to be the dominant factor influencing survival in this group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271–825.

    Article  PubMed  CAS  Google Scholar 

  2. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10years. Ann Surg 2001;234:63–70.

    Article  PubMed  CAS  Google Scholar 

  3. Lee NW, Wong J, Ong GB. The surgical management of primary carcinoma of the liver. World J Surg 1982;6:66–75.

    Article  PubMed  CAS  Google Scholar 

  4. Levinsky NG. Organ donation by unrelated donors. N Engl J Med 2000;343:430–432.

    Article  PubMed  CAS  Google Scholar 

  5. Okada S. Chemotherapy for Hepatocellular Carcinoma. In Okuda K, Tabor E, eds. Liver Cancer. New York: Churchill Livingstone; 1997, p 8.

    Google Scholar 

  6. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676–1681.

    PubMed  CAS  Google Scholar 

  7. Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421–427.

    Article  PubMed  CAS  Google Scholar 

  8. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1 164–1171.

    Article  CAS  Google Scholar 

  9. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11:181–184.

    Article  PubMed  CAS  Google Scholar 

  10. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256–1261.

    Article  Google Scholar 

  11. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. Radiology 2002;224:47–54.

    Article  PubMed  Google Scholar 

  12. Livraghi T. Role of percutaneous ethanol injection in the treatment of hepatocellular carcinoma. Dig Dis 2001;19:292–300.

    Article  PubMed  CAS  Google Scholar 

  13. Seidenfeld J, Korn A, Aronson N. Radiofrequency ablation of unresectable primary liver cancer. J Am Coll Surg 2002; 194:813–828.

    Article  PubMed  Google Scholar 

  14. Ausman RK. Development of a technic for isolated perfusion of the liver. N Y State J Med 1961;61:3393–3397.

    Google Scholar 

  15. Alexander HR, Bartlett DL, Libutti SK. Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am 1998;4:2–11.

    PubMed  Google Scholar 

  16. Alexander HR, Bartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16:1479–1489.

    PubMed  CAS  Google Scholar 

  17. Oldhafer KJ, Lang H, Frerker M, et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery 1998;123:622–631.

    PubMed  CAS  Google Scholar 

  18. Hafstroöm LR, Holmberg SB, Naredi PLJ, et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 1994;3:103–108.

    Article  CAS  Google Scholar 

  19. Alexander HR, Libutti SK, Bartlett DL, et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000;6:3062–3070.

    PubMed  CAS  Google Scholar 

  20. Barker WC, Andrich MP, Alexander HR, Fraker DL. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 1995;22:1242–1248.

    Article  PubMed  CAS  Google Scholar 

  21. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750.

    Article  PubMed  CAS  Google Scholar 

  22. Alexander HR, Bartlett DL, Fraker DL, Libutti SK. Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver. In DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: JB Lippincott, 1996, pp 1–19.

    Google Scholar 

  23. Alexander HR, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist 2000;5:416–424.

    Article  PubMed  CAS  Google Scholar 

  24. BartlettDL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001;129:176–187.

    Article  Google Scholar 

  25. Libutti SK, Bartlett DL, Fraker DL, Alexander HR. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg 2000; 191:519–530.

    Article  PubMed  CAS  Google Scholar 

  26. Carroll NM, Alexander HR Jr. Isolation perfusion of the liver. Cancer J 2002;8:181–193.

    Article  PubMed  Google Scholar 

  27. Weinreich DM, Alexander HR. Transarterial perfusion of liver metastases. Semin Oncol 2002;29:136–144.

    Article  PubMed  Google Scholar 

  28. Hoekstra HJ, Naujocks T, Schraffordt-Koops H, et al. Continuous leaking monitoring during hyperthermic isolated regional perfusion of the lower limb: Techniques and results. Reg Cancer Treat 1992;4:301–304.

    Google Scholar 

  29. Klaase JM, Kroon BBR, van Geel AN, Eggermont AMM, Franklin HR. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993;80:1 124–1126.

    Article  CAS  Google Scholar 

  30. Kitamura K, Kuwano H, Matsuda H, Toh Y, Masuda H, Sugimachi K. Synergistic effects of intratumor administration of cis-diamminedichloroplatinum(II) combined with local hyperthermia in melanoma bearing mice. J Surg Oncol 1992; 51:188–194.

    Article  PubMed  CAS  Google Scholar 

  31. Miller RC, Richards M, Baird C, Martin S, Hall EJ. Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. Int J Hyperthermia 1994; 10:89–99.

    PubMed  CAS  Google Scholar 

  32. Klostergaard J, Leroux E, Siddik ZH, Khodadadian M, Tomasovic SP. Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res 1992;52:5271–5277.

    PubMed  CAS  Google Scholar 

  33. Eggermont AMM, Schraffhorst Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg 1996;224:756–765.

    Article  PubMed  CAS  Google Scholar 

  34. Olieman AFT, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997;4:64–69.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Metabolism Section, Surgery Branch, National Cancer Institute/NIH Building 10, Room 2B07, 20892-1502, Bethesda, MD

    Elizabeth D. Feldman M.D., Peter C. Wu M.D., Tatiana Beresneva M.D., Cynthia Helsabeck R.N., Montessa Rodriguez R.N., David L. Bartlett M.D., Steven K. Libutti M.D., James F. Pingpank M.D. & H. Richard Alexander M.D. (Head)

Authors
  1. Elizabeth D. Feldman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter C. Wu M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tatiana Beresneva M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cynthia Helsabeck R.N.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Montessa Rodriguez R.N.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David L. Bartlett M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Steven K. Libutti M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. James F. Pingpank M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H. Richard Alexander M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Richard Alexander M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldman, E.D., Wu, P.C., Beresneva, T. et al. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg 8, 200–207 (2004). https://doi.org/10.1016/j.gassur.2003.11.005

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.gassur.2003.11.005

Key words

Search

Navigation